Axim taps CRO for cannabinoid product development and clinical trials

23-Mar-2017 - Last updated on 23-Mar-2017 at 15:34 GMT

Axim Biotech has contracted an ophthalmology CRO to support upcoming product development and clinical trials for its cannabinoid-based therapeutics.

Axim Biotechnologies’ flagship products include CanChew, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum.

As previously reported, the company has enrolled 40 patients for its Canchew Plus chewing gum Ph II clinical trial.

Now, the company contracted Ora, Inc., a global contract research organization (CRO) to help advance its AX-1603 and AX-1606 clinical programs.

George E. Anastassov, MD, DDS, and CEO of AXIM Biotech, told us the contract research organization (CRO) will provide product development based on Axim’s filed intellectual property (IP).

“Within the next eight weeks Ora will develop a plan of action for two trials,” said Anastossov. The Ph II clinical trials will examine the ability of cannabinoids to treat glaucoma and dry eye syndrome.

“Axim is extremely excited to begin the program,” Anastossov added.

The program will be run under the supervision of Prof. Robert Ritch, an Axim advisory board member and Surgeon Director Emeritus and Chief of Glaucoma Services at New York Eye and Ear Infirmary of Mount Sinai School of Medicine in New York (NYEE).

(Feature image: iStock/petdcat)